Philadelphia

Az itteni vizsgálatok

Miről szól a helyszín 117 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák21 vizsgálat
• Máj- és epeúti rák11 vizsgálat
• Prosztatarák9 vizsgálat
• Krónikus obstruktív tüdőbetegség (COPD)8 vizsgálat
• Szívelégtelenség7 vizsgálat
• Amiloidózis6 vizsgálat
• Áttétes emlőrák6 vizsgálat
• Petefészekrák6 vizsgálat
• Gyomor- és nyelőcsőrák5 vizsgálat
• Hasnyálmirigyrák5 vizsgálat
• 2-es típusú cukorbetegség4 vizsgálat
• Asztma4 vizsgálat
• és még 35

Fázis

• 3. fázis64 vizsgálat
• 2. fázis22 vizsgálat
• 1. fázis9 vizsgálat
• 1/2. fázis8 vizsgálat
• 2/3. fázis3 vizsgálat
• 4. fázis2 vizsgálat

Állapot

• Fut, nem toboroz51 vizsgálat
• Toboroz26 vizsgálat
• Lezárult22 vizsgálat
• Még nem toboroz14 vizsgálat
• Leállították2 vizsgálat
• Visszavonták2 vizsgálat

Fő szponzor

• AstraZeneca94 vizsgálat
• Alexion Pharmaceuticals, Inc.11 vizsgálat
• Arcus Biosciences, Inc.3 vizsgálat
• Acerta Pharma BV2 vizsgálat
• MedImmune LLC2 vizsgálat
• és még 5

Futó vizsgálatok

• Még nem toboroz

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Toboroz

  A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

  NCT07735637· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

  NCT07816666· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  NCT07662109· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  NCT07662213· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· 2. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07088926· 2. fázis· AstraZeneca· Forrás

• Toboroz

  ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy

  NCT07218887· 1/2. fázis· Alexion Pharmaceuticals, Inc.· Forrás

  Contact: Joseph Puhl

• Toboroz

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· 2/3. fázis· Daiichi Sankyo· Forrás

• Toboroz

  DESTINY-PANTUMOUR04

  NCT07124000· AstraZeneca· Forrás

• Még nem toboroz

  LTFU for All Cell and Gene Therapy Studies

  NCT06194461· AstraZeneca· Forrás

• Toboroz

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· AstraZeneca· Forrás

• Toboroz

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

  NCT06932263· 2. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  NCT06883305· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  NCT06677060· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

  NCT06830629· 2. fázis· Maze Therapeutics· Forrás

  Contact: Maze Therapeutics

• Toboroz

  Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

  NCT06651970· 4. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  NCT06564038· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

  NCT06608927· 3. fázis· Arcus Biosciences, Inc.· Forrás

• Toboroz

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

  NCT06564844· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

  NCT06535607· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  NCT06455449· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  NCT06218914· 1. fázis· AstraZeneca· Forrás

• Toboroz

  An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

  NCT05835310· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of AZD0754 in Participants With Metastatic Prostate Cancer

  NCT06267729· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

  NCT06346392· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

  NCT06040099· 2. fázis· AstraZeneca· Forrás

• Toboroz

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Toboroz

  Observational Study Protocol: LIVER-R

  NCT06252753· AstraZeneca· Forrás

• Fut, nem toboroz

  A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

  NCT06084884· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma

  NCT05951959· 2. fázis· AstraZeneca· Forrás

• Toboroz

  AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  NCT06106945· 1/2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· 3. fázis· AstraZeneca· Forrás

Showing 50 of 91.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Máj- és epeúti rák5 toboroz
• 2-es típusú cukorbetegség4 toboroz
• Szívelégtelenség4 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)3 toboroz
• Méhtestrák3 toboroz
• Prosztatarák3 toboroz
• Amiloidózis2 toboroz
• Elhízás2 toboroz
• Fej-nyaki daganatok2 toboroz
• Hodgkin-limfóma2 toboroz
• Krónikus limfoid leukémia (CLL)2 toboroz
• Krónikus vesebetegség2 toboroz
• Méhnyakrák2 toboroz
• Mielóma multiplex2 toboroz
• Petefészekrák2 toboroz
• Tüdőrák2 toboroz
• 1-es típusú cukorbetegség1 toboroz
• Asztma1 toboroz
• Áttétes emlőrák1 toboroz
• Bronchiectasis1 toboroz
• Dermatomyositis and polymyositis (myositis)1 toboroz
• Dilated cardiomyopathy1 toboroz
• Follikuláris limfóma1 toboroz
• Gyermekkori daganatok1 toboroz
• Hasnyálmirigyrák1 toboroz
• Hólyagrák1 toboroz
• Idiopátiás tüdőfibrózis1 toboroz
• Köpenysejtes limfóma1 toboroz
• Koszorúér-betegség1 toboroz
• Lupus (SLE)1 toboroz
• Melanóma1 toboroz
• Mezotelióma1 toboroz
• Neuroendokrin daganatok1 toboroz
• Pajzsmirigyrák1 toboroz
• Szarkóma1 toboroz
• Testicular cancer1 toboroz
• Vesedaganat1 toboroz

Lezárt vizsgálatok

• Lezárult

  A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

  NCT06299826· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

  NCT06120075· 1. fázis· Arcus Biosciences, Inc.· Forrás

• Lezárult

  A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

  NCT06075095· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  NCT06129864· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· 3. fázis· AstraZeneca· Forrás

• Leállították

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

  NCT05742802· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

  NCT05408039· AstraZeneca· Forrás

• Lezárult

  Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

  NCT05329194· 4. fázis· AstraZeneca· Forrás

• Leállították

  Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

  NCT05218096· 2. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

  NCT05158387· 3. fázis· AstraZeneca· Forrás

• Lezárult

  MEOI and HRQoL in CLL Patients Treated With BTKis

  NCT04938141· AstraZeneca· Forrás

• Lezárult

  A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

  NCT04706923· 2. fázis· SymBio Pharmaceuticals· Forrás

• Lezárult

  Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

  NCT04986202· 2/3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

  NCT04564027· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

  NCT04104672· 1. fázis· Arcus Biosciences, Inc.· Forrás

• Lezárult

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Tezepelumab COPD Exacerbation Study

  NCT04039113· 2. fázis· AstraZeneca· Forrás

• Lezárult

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Disease Registry of Patients With Mantle Cell Lymphoma

  NCT03816683· AstraZeneca· Forrás

• Lezárult

  A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

  NCT03759366· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)

  NCT03373045· AstraZeneca· Forrás

• Lezárult

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

  NCT01078662· 2. fázis· AstraZeneca· Forrás

• Lezárult

  A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

  NCT00600496· 1. fázis· AstraZeneca· Forrás